Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial
International Journal of Clinical Oncology,  Clinical Article

Uemura H et al. – Simultaneous administration of zoledronic acid (ZOL) and maximal androgen blockade (MAB) as initial treatment delayed time to progression (TTP) in bone–metastatic prostate cancer patients. Initial treatment with ZOL has the possibility of anti–tumor activity to delay disease progression.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Urology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Urology Articles

Indexed Journals in Urology: Urology, Journal of Urology, European Urology, The Prostatemore